Key result
Adamts2 silencing regulated the expression of genes within a hypertrophy-related module and impaired isoproterenol-induced cellular hypertrophy in neonatal rat ventricular myocytes.
Why the study?
Does Adamts2 silencing impair isoproterenol-induced cellular hypertrophy in preclinical models?
Does Adamts2 silencing impair isoproterenol-induced cellular hypertrophy in preclinical models?
Adamts2 was identified and validated as a driver of isoproterenol-induced cardiac hypertrophy, offering potential diagnostic and therapeutic insights for heart failure.
No takes yet. Share an insight, caveat, or question.
Adamts2 merits further preclinical exploration as hypertrophy regulator; hypothesis-generating and should not yet inform clinical practice.
Rau et al. (2016) studied Isoproterenol-induced cardiac hypertrophy and cardiomyopathy. Adamts2 silencing via small interfering RNA was evaluated on Gene expression regulation and cellular hypertrophy. Adamts2 silencing regulated the expression of genes within a hypertrophy-related module and impaired isoproterenol-induced cellular hypertrophy in neonatal rat ventricular myocytes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: